Oral DNA Demethylating Agents and Epigenetic Targeting in Adult T-Cell Leukemia/Lymphoma
- 1Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan
- 2Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan
Abstract
DNA methylation plays a critical role in gene regulation and is frequently dysregulated in hematological malignancies such as myelodysplastic syndromes and acute myeloid leukemia. DNA demethylating agents have therefore emerged as important therapeutic options. However, conventional DNA demethylating agents require parenteral administration, which limits their long-term use and patient convenience. In this review, we aim to provide an overview of recent advances in the development of orally available DNA demethylating agents and discuss their therapeutic applications in hematological malignancies. Orally available DNA demethylating agents, such as CC-486 (oral azacitidine) and ASTX727 (a fixed-dose combination of oral decitabine and the cytidine deaminase inhibitor cedazuridine), have been developed to overcome these limitations and enable sustained drug exposure. In addition, OR-2100, a novel oral prodrug of decitabine, has been shown to exhibit improved pharmacokinetic properties and reduced hematologic toxicity in preclinical studies. These findings suggest that orally available DNA demethylating agents may expand therapeutic options, particularly for hematological malignancies such as adult T-cell leukemia/lymphoma.
Related
- Targeting ATR/CHK1 pathway in acute myeloid leukemia to overcome chemoresistance
- CONVERGENT MODULATION OF THE EPIGENETIC MACHINERY BY NATURAL COMPOUNDS IN LEUKEMIA MODELS
- Targeting PTPN2-mediated dephosphorylation destabilizes c-MYC and suppresses acute myeloid leukemia survival
- Targeting Artemis sensitizes acute lymphoblastic leukemia cells to topoisomerase 2 poisons by disrupting DNA-PKcs-dependent repair.
- Targeting lysine acetyltransferase 6A/B in cancer: a conceptual and translational review of epigenetic regulation, immune microenvironment remodeling, and the dual-compartment hypothesis
BibTeX
@article{yamamoto2026oral,
title = {{Oral DNA Demethylating Agents and Epigenetic Targeting in Adult T-Cell Leukemia/Lymphoma}},
author = {Yuta Yamamoto and Hiroshi Ureshino and Shinya Kimura},
journal = {Oncology Research},
year = {2026},
month = oct,
doi = {10.32604/or.2026.084740},
url = {https://doi.org/10.32604/or.2026.084740},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Oral DNA Demethylating Agents and Epigenetic Targeting in Adult T-Cell Leukemia/Lymphoma
AU - Yuta Yamamoto
AU - Hiroshi Ureshino
AU - Shinya Kimura
PY - 2026
DA - 2026/10/28
JO - Oncology Research
DO - 10.32604/or.2026.084740
UR - https://doi.org/10.32604/or.2026.084740
AB - DNA methylation plays a critical role in gene regulation and is frequently dysregulated in hematological malignancies such as myelodysplastic syndromes and acute myeloid leukemia. DNA demethylating agents have therefore emerged as important therapeutic options. However, conventional DNA demethylating agents require parenteral administration, which limits their long-term use and patient convenience. In this review, we aim to provide an overview of recent advances in the development of orally available DNA demethylating agents and discuss their therapeutic applications in hematological malignancies. Orally available DNA demethylating agents, such as CC-486 (oral azacitidine) and ASTX727 (a fixed-dose combination of oral decitabine and the cytidine deaminase inhibitor cedazuridine), have been developed to overcome these limitations and enable sustained drug exposure. In addition, OR-2100, a novel oral prodrug of decitabine, has been shown to exhibit improved pharmacokinetic properties and reduced hematologic toxicity in preclinical studies. These findings suggest that orally available DNA demethylating agents may expand therapeutic options, particularly for hematological malignancies such as adult T-cell leukemia/lymphoma.
SN - 0965-0407
SN - 1555-3906
ER -